Posted by CryptoCoinsNews on September 25, 2018 08:24:04 Canonical Biologies is an Australian biotech company that specialises in the production of novel, biologically engineered pharmaceutical drugs.
The company is currently focused on the development of a biologic, which is a type of natural product made from a genetically engineered gene.
Canonical’s biological products are used for a range of purposes including the treatment of diseases such as cancer, Parkinson’s disease and heart disease.
Canonics products are also used in a range for other purposes, including the production and supply of biologicides, anti-fungal and antibacterial products, antiobiotics, food and pharmaceuticals, biofuels and bioengineering.
Canons Bio-Tech is a biotechnology company that is focused on developing novel biologicals for the treatment and prevention of disease.
The company was founded by Andrew Gartland, an academic at the University of NSW and Dr. Stephen Gartlander.
Gartland was an early investor in Canonical Bio-tech and has now left the company to start his own biotechnology firm.
He said that he is very proud of the success of the company.
Garts life at Canonical was a passion project which he started in 2012 when he was studying chemical engineering.
He is now working with the company on developing the company’s biocompatible gene-editing technology.
Canontons Bio Tech will be working with a number of major pharmaceutical companies in Australia, such as the National Health and Medical Research Council (NHMRC), Abbott Laboratories, Abbott Healthcare and the Australian Biotechnology and Biological Sciences Organisation (ABBSAO).
Canonicals biocommunications is also working with pharmaceutical giants such as AstraZeneca and Pfizer, and the Biotechnology Industry Regulatory Authority (BIRA).
Gartlander said that it was an exciting time to be involved in this new industry.
Canontas mission is to create a new generation of innovative biologis which will be available for use by the Australian community in the coming years.
Garth, who also works at Canonicals Biotech, said that the success the company has seen with the new product is indicative of the kind of company Canonical is.
He said that his main focus was to create new products that are safe, that are easy to use, and that were easily available in Australia.
Canons BioTech’s research will continue in the next year.
Gestling said that Canonical’s business model was based on providing an efficient supply chain, and not relying on the need to go into the manufacturing of new products.
Canonaics Bio Tech’s focus is on the supply chain and its future products, he added.